Compare Eli Lilly And Co (LLY) vs Banco Santander SA (SAN) Price & Performance

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Banco Santander (SAN) trades at $14.83, up 0.92% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q2 2026 earnings, beating estimates in Q1 but missing in Q2, while net income grew to $14.10 billion in 2025. Recent news includes Federal Reserve approval for its $12 billion acquisition of Webster Bank, enhancing its U.S. footprint.

Outlook is supported by analyst consensus (64% buy ratings) and record profitability, but risks include volatile earnings, high debt levels, and integration challenges from acquisitions. The stock's valuation appears reasonable with a P/E of 14.4, offering potential for growth if execution remains strong amid economic uncertainties.